Institute for Interdisciplinary

Innovation in healthcare

New Working Paper by Elise Petit

How do pharmaceutical patenting practices affect legal uncertainty and, ultimately, healthcare systems? This working paper by Elise Petit examines how divisional applications and secondary patents influence the length of patent examination at the European Patent Office. Drawing on data from 15,737 patent applications linked to medicines, the authors find that patent families and secondary patents tend to remain pending significantly longer than single applications, particularly for high-value drugs. The analysis also shows that these delays are associated with the combined use of several procedural mechanisms across and within patent families. The findings shed new light on how patent procedures can prolong legal uncertainty around medicines and raise important questions for competition, pharmaceutical innovation, and healthcare expenditure.

Read the full working paper here

I3h The Lancet Publication

I3h researchers from life sciences and economics Hilde Stevens, Georges Siotis, Micael Castanheira, Mathias Dewatripont, Sanae Akodad, Sam Daems and Michel Goldman have, together with Alain Fischer, published the paper Rebalancing innovation, affordability, and access for orphan drugs in the European Union in the journal The Lancet – Regional Health Europe.

The article can be found here. It starts from the observation that orphan drug policy in the European Union faces a double price-and-innovation gap: a small fraction of rare diseases receive important resources while the overwhelming majority are under- or un-researched, leaving most rare disease patients facing high unmet medical needs. To address this double problem of innovation and affordability and access, we propose an integrated strategy to develop affordable innovative solutions for patients with rare diseases. It would include a set of measures included in the EU Pharma package, the EU Biotech Act and the Draghi report, complemented by public-private Specific Purpose Vehicles to de-risk innovative endeavours and joint procurement of orphan drugs to facilitate their availability to European patients.

I3h Reading Seminar : Serge Goldman - Ethical Aspects of Artificial Intelligence Implementation in Medical Research

Our guest was Serge Goldman, Senior Professor of Neurology and Nuclear Medicine; Expert in Molecular Brain Imaging and Research Evaluation. His presentation focused on Ethical Aspects of Artificial Intelligence Implementation in Medical Research, an increasingly critical topic in today’s evolving healthcare landscape.

AI in healthcare at Assises de l’eSanté Lux-Health

At the forefront of digital health innovation, the Assises de l’eSanté Lux-Health continues to bring together healthcare professionals, researchers, and innovators to explore how technology is transforming patient care.

The 2026 edition focuses on a key question shaping the future of healthcare: how artificial intelligence is becoming part of patients’ everyday lives and what this means for clinical practice, care relationships, and the organization of health services. With over 70 expert speakers and a strong emphasis on collaboration, the event offers a unique platform to exchange ideas, share experiences, and build meaningful connections across the healthcare ecosystem.

We are particularly proud to highlight the participation of I3h alumna Tatiana Revenco, whose presence at this leading event reflects both her expertise and her commitment to advancing healthcare innovation. Her journey exemplifies the impact of our alumni community in shaping the future of medicine and digital health.

Find out more

What do cancer patients truly value in their care journey?

What do cancer patients truly value in their care journey?

A new study, “Self-reported patient experiences in a peer-support community: What do cancer patients value?”, explores this question by analyzing unguided patient narratives shared in the French-speaking podcast “Naître princesse, devenir guerrière.” The study was led by our postdoctoral researcher, Florence Horicks, whose work focuses on better understanding and integrating patient perspectives into healthcare research and practice.

Rather than relying on structured surveys or clinical outcome measures, the team examined 31 spontaneous patient stories recorded between 2021 and 2024. These narratives, shared within a peer-support community, offer a powerful window into what matters most to patients beyond traditional healthcare metrics.

🔎 Six key dimensions of patient value emerged:

  • Peer support: The unique solidarity and understanding found within patient communities
  • Empowerment: Reclaiming agency and an active role in one’s care journey
  • Relationships with healthcare professionals: Complex but central to the experience
  • Quality of life: Balancing treatment with meaningful living
  • Cancer as an opportunity: Reframing adversity and redefining priorities
  • Individuality: Recognizing each patient’s unique story and needs

💡 Key insight: Patients often define value not only through clinical outcomes, but through meaning, connection, and the ability to act on what matters most to them.

This research highlights the untapped potential of online health communities and patient-led narratives as rich sources of insight for building more patient-centered, participatory, and value-driven oncology systems.

Listening to patient voices, especially when they speak freely among peers, can reshape how we approach care, research, and policy.

Read more in Frontiers

I3h Reading Seminar - 16 March 2026 : Patient Involvement as a Lever of Empowerment in Health Research

On March 16 from 12:30 to 14:00, the I3h Institute will host its next Reading Seminar at Université libre de Bruxelles (Campus Solbosch, Building R42) and online.

The session will feature Florence Horicks, researcher at the I3h Institute and Pôle Santé (ULB), who will present her work on how to better define and strengthen “patient value” in oncology research. Conducted within a transdisciplinary team funded by the King Baudouin Foundation, her research explores patient engagement, transdisciplinary collaboration, and quality of life in cancer survivorship through participatory, narrative, and citizen-based methods. The seminar will be of particular interest to healthcare researchers, clinicians, policymakers, patient advocates, and anyone interested in participatory research and innovation in cancer care.

To attend in person, please contact ncheikh@i3health.eu by March 12.
To attend online, please register here

I3h Reading Seminar - Niklas Blomberg on Collaborative Innovations - 2 March 2026

On March 2, 2026, the I3h Institute will host its next Reading Seminar, dedicated to the theme “Collaboration for Innovation” (ULB, Campus Solbosch, R42 Building).

The session will be delivered by Dr Niklas Blomberg, Executive Director of the Innovative Health Initiative (IHI). With extensive experience in academia, industry and European research infrastructures, Dr Blomberg has a strong expertise on how cross-sector partnerships can drive transformative impact in the life sciences.

This seminar will explore, among others, how strategic collaboration between academia, industry, public authorities, regulators and civil society strengthens Europe’s health research ecosystem and accelerates innovation, how public–private partnerships mobilise investment, align strategic priorities and leverage complementary expertise to address unmet public health needs.

This session is particularly relevant for policymakers, researchers, healthcare professionals, economists and all stakeholders interested in building resilient and competitive health innovation ecosystems.

– To attend in person, please contact ncheikh@I3health.eu until February 26.
– Register to attend online

How can we communicate better for evidence-informed policy-making in crisis management?

The “Getting Ready for Trouble” symposium and workshop recently took place in Brussels on November 27 and 28 (ULB, Campus Solbosch), bringing together policymakers, stakeholders and leading researchers to discuss how communication can better support evidence-informed policy-making in times of crisis.

Over two days of discussions and interactive sessions, participants explored key challenges related to pandemic preparedness and response, including the complexity of communicating scientific evidence under uncertainty, aligning stakeholder perspectives, and supporting decision-making in high-pressure environments.

I3h contributions

We are pleased to share that Caroline Van Swieten and Mathias Dewatripont both contributed to the event through dedicated presentations, highlighting current challenges and opportunities to improve communication between science and policy during crisis management. Caroline stressed principles that should guide training programmes in both ‘quiet times’ and ‘crisis times’. As for Mathias, he built upon his experience as a ‘general academic economist’ who was involved in Belgian expert groups during the COVID-19 pandemic (GEES and GEMS).

To support dissemination and further discussion beyond the event, we are making their slides available here :

New Publication : Michel and Serge Goldman publish a new article in The Conversation on the rise of patient partners

A new article has just been published in The Conversation: “The rise of patient partners in healthcare.”

Co-authored by Michel Goldman, Honorary President of I3h, and Serge Goldman, the article explores the growing role of patient partners and the transformation this shift is bringing to healthcare systems. It highlights a move toward more collaborative models of care, where patients’ lived experience and expertise are increasingly integrated into clinical decision-making, institutional practices, and research.

Read More in The Conversation

Launch of the 10th edition of the I3h Interdisciplinary Program in Healthcare Innovation

The 10th edition of the I3h Interdisciplinary Program in Healthcare Innovation officially started on 13 February 2026, with the first Module held at ULB Erasme Campus (Brussels), with 120 students registered.

This opening session welcomed a panel of experts and speakers Michel Goldman (I3h Institute, ULB), Hilde Stevens (I3h Institute, ULB), Niklas Blomberg (Innovative Health Initiative – IHI), Bruno Flamion (UNamur / Viatris Innovation), Dimitrios Tzalis (Taros Chemicals GmbH), Daphné Derouane (UCB), Charlotte Peters (HR One) and Maria Dutarte (EUPATI).

This first module introduced the program by highlighting the importance of interdisciplinary collaboration, trust-based partnerships, and the need to connect expertise across sectors to address major healthcare challenges.

PhD candidate Sanae Akodad graduates with honours

We are immensely proud to announce that our PhD candidate Sanae Akodad has successfully graduated with honours, marking a historic milestone as the first PhD graduate from the Faculty of Medicine at I3h. This achievement reflects years of dedication, perseverance and academic excellence by Doctor Akodad. Reaching this moment together is deeply meaningful for our entire Institute, and we celebrate it with great pride and genuine emotion. This milestone not only honors an outstanding individual accomplishment, but also represents the collaborative work and support from I3h co-director and promoter Hilde Stevens.

I3h’s PhD student Sanae Akodad has just published a new article in Frontiers in Medicine

Discover why patients with the most urgent needs still face unequal access to breakthrough therapies worldwide. This article compares the United States, EU, China and Japan, revealing how differing definitions of unmet medical need, varied regulatory timelines and fragmented early‑access programs keep life‑saving treatments out of reach for many.

It highlights pioneering schemes—FDA Breakthrough Therapy, EMA PRIME, Japan’s Sakigake, and China’s new reforms—while exposing the persistent gaps caused by misaligned health‑technology assessments. Finally, it proposes a bold shift to adaptive licensing and international, benefit‑risk‑focused governance, turning uncertainty into a shared responsibility and paving the way for fairer, faster access to innovative medicines.

Read the full article

Florence Horicks will present an abstract from the Symphony of Us project at the Citizen Science for Health Conference in Zurich

Mark your calendars for November 6th and 7th 2025.

Find out more

3-daagse opleiding “Economische evaluaties van medische interventies”
(Leuven & Sint-Martens-Latem)

Als auteur van de nieuwe Belgische richtlijnen voor economische evaluaties en budget impact analyses gaan we dieper in op de aandachtspunten (en valkuilen) bij het opstellen/uitvoeren/(kritisch) evalueren van economische evaluaties. Daarnaast komen de impact van de nieuwe Europese HTA regelgeving, hoe de impact op de levenskwaliteit meten, hoe een evidence-based Markov model opstellen, en nog zoveel meer, aan bod. Voor meer details verwijzen we naar de brochure in bijlage.
We verwelkomen u graag in een professioneel kader op de volgende data:
– 25-27 maart, 2026 (Sint-Martens-Latem – Auberge du Pêcheur) – Nog plaatsen beschikbaar
– 23-25 september, 2026 (Leuven – Park Inn by Radisson Leuven) – Nieuwe sessie! Inschrijvingen open
Deze interessante en interactieve opleiding wordt in het Nederlands gegeven aan een groep van maximum 20 deelnemers. Met veel enthousiasme & passie zorgen we voor een maximale overdracht van kennis, opgebouwd na meer dan 20 jaar praktische ervaring in het domein van HTA en economische evaluaties.
Voor meer informatie of om u in te schrijven kan u rechtstreeks contact opnemen met Mattias Neyt (mattias.neyt@me-ta.eu)
More details

Une nouvelle ère pour les vaccins et la santé mondiale? A l’Europe de prendre la main – Carte blanche de Michel Goldman 

Article du Daily Science

Read the article

Celebrating 10 Years of the Institute for Interdisciplinary Innovation in Healthcare

A great milestone bringing together experts, researchers, and leaders to reflect on a decade of progress and the challenges ahead in healthcare.

Drug Repurposing board game
More details

A word from Michel Goldman

Michel Goldman, President of the I3h  Institute, introduces the EU4Health Impact and Integration Initiative.

Eu4health Michel video pill

Watch the video

Michel Goldman awarded the 2024 Blaise Pascal Medal laureate in Medicine and Life Sciences.

His commitment to advancing scientific knowledge and fostering interdisciplinary collaboration exemplifies the spirit of the Blaise Pascal Medal, making him a truly deserving recipient of this prestigious honor.

Michel Goldman alt text

Link to article

Health Innovation, next generation payment & pricing models

Save the date

Drug Repurposing board game
More details

La lutte contre les futures pandémies doit s’organiser sans les États-Unis

Une tribune du Professeur Michel Goldman (ULB), président de l’Institut I3h, ancien directeur exécutif de l’Initiative Européenne pour les Médicaments Innovants, membre de l’Académie Royale de Médecine de Belgique.

Article in La Libre

Link to article

Réflexions sur l’avenir de la médecine inspirées par la pandémie de COVID-19

Comment la pandémie de Covid-19 a-t-elle permis et propulsé des avancés majeures en médecine ? Quelques pistes sur l’évolution de la recherche et des technologies
médicales…

Article published in “L’Artichaut” edited by CEPULB. Michel Goldman, January 2025.
Link to article

Mathias Dewatripont’s presentation at Collège de France

Mathias Dewatripont presented at an event of the Collège de France in Paris on November 13 on the Future of European Competitiveness, organised by Philippe Aghion, with the presence of Mario Draghi and President Emmanuel Macron.

Watch the recording

AI in Healthcare: Key Challenges and the Regulatory Framework for Clinical Adoption

Artificial intelligence is becoming increasingly integrated into healthcare, from administrative support and medical documentation to diagnosis, imaging, triage and personalised medicine. In this narrative review, Tatiana Revenco, expert in European health-data regulation and lecturer at the I3h Institute, examines the opportunities and risks associated with AI and provides an accessible overview of the European regulatory framework governing its use in healthcare.

The article focuses in particular on the EU AI Act, the classification of AI systems according to their level of risk, and the responsibilities of the different actors involved in their development and deployment. For high-risk AI systems used in clinical settings, transparency, human oversight and appropriate training of healthcare professionals are highlighted as essential conditions for safe and responsible adoption. Ultimately, the review stresses that successful integration of AI into healthcare requires not only technological performance, but also interdisciplinary collaboration, clear governance and continued investment in education and skills.

Read the full article here

Sam Daems addresses the European Parliament's Committee on Public Health

Sam Daems recently addressed the Committee on Public Health during its ordinary meeting, calling for a more deliberate and coordinated approach to pediatric oncology research and innovation in Europe.

In his speech, he highlighted the need to consciously design Europe’s pediatric oncology translation system and make better use of existing resources and policy levers. By concentrating scarce resources on the most promising opportunities and creating clearer pathways from research to clinical application, Europe can give promising science a better chance of becoming life-saving treatments for children.

The full meeting is available here.

Medical AI: Are Osler's Principles Lost in Translation?

This article by Michel Goldman, Elie Cogan, and Serge Goldman is a preprint version of an article submitted for publication. It has not yet been accepted or published, and may therefore be subject to revision before its final version is published.

Click here to read the preprint

I3h Reading Seminar : Elise Petit - Strategic Divisional Filings in Pharmaceutical Patents: A Moving Target for Generic Competition

Elise Petit was our last speaker of the academic year. In the pharmaceutical sector, generic competition is expected to begin once the original 20 (+5) years of patent protection come to an end. In practice, however, the path to market is often less straightforward. Drawing on European patent records and pharmaceutical sales data, this seminar explores how the strategic use of divisional applications (a seemingly technical European Patent Office procedure) prolongs legal uncertainty around the scope of patent protection and turns patent portfolios into moving targets, ultimately making generic entry harder to plan, riskier to launch, and more prone to delay.

Health Roundtable at the ECARES Conference Honouring Mathias Dewatripont

On May 7 2026, I3h will co-organize a roundtable on health as part of the two-day conference ECARES is organizing – with the Solvay Brussels School of Economics and Management – for the retirement of its founding Director Mathias Dewatripont (https://ecares.ulb.be/dewatripont-fest/). The conference will bring together leading researchers and prominent stakeholders from policy and society.

The conference will be held on May 6 and 7, 2026 (in room R42.5.503 of ULB’s R building situated on 42, avenue Roosevelt), and the health roundtable will take place on May 7 from 16:30 until 17:45 (followed by a drink). It will bring together our I3h colleagues Micael Castanheira (as moderator) and Michel Goldman, as well as Alain Fischer (Collège de France and Institut Imagine), Marius Gilbert (ULB, Vice-Rector for Research) and Erika Vlieghe (University of Antwerp and UZA).

Participants are warmly welcome; however, registration is required : dewatripont.fest@ulb.be

I3h Publication in La Libre Belgique: AI in Medicine - Co-Pilot or Pilot?

In a recent opinion article published in La Libre Belgique, Serge Goldman and Michel Goldman, Professors at ULB, examine the evolving role of artificial intelligence in medical practice.

Their contribution explores a fundamental question: as AI systems become increasingly powerful – and potentially autonomous – should they assist physicians, or replace key dimensions of medical decision-making?

Beyond technological performance, the article stresses the need to preserve the physician–patient relationship and to ensure that innovation strengthens, rather than destabilizes, the foundations of healthcare systems.

Read more in La Libre

Competition-friendly industrial policy

By Philippe Aghion, Mathias Dewatripont & Patrick Legros

In May 2025, Philippe Aghion, Mathias Dewatripont and Patrick Legros published a paper entitled “Competition-Friendly Industrial Policy”, exploring how industrial policy can be designed to address market failures while avoiding the risk of protecting inefficient firms.

The authors argue that industrial and competition policies should be seen as complementary, rather than conflicting. They highlight the benefits of well-targeted, sector-specific subsidies and stress the importance of maintaining competitive markets as a key condition for sustainable industrial development. Their analysis builds on both theoretical insights and empirical evidence, including findings from Chinese industrial policy and from the US BARDA funding of competing projects to develop COVID-19 vaccines.

Presentation at the Congrès des Économistes (27 November 2025)

On 27 November 2025, Mathias Dewatripont presented this work at the Congrès des Économistes, hosted by the National Bank of Belgium, during the conference dedicated to public finance challenges and solutions : Dewatripont-Congrès-des-Economistes-27-11-2025

The presentation took place within the commission entitled: “Finances publiques et compétitivité – politique industrielle – autonomie stratégique”,
chaired by Alexis Walckiers (ULB and E-CA) and Reinhilde Veugelers (Professor at KU Leuven and I3h Board member).

The session also included a presentation by Sofia Amaral-Garcia focusing on the biopharmaceutical sector: Congrès 2025_ Commission 4_AmaralGarcia

More information about the conference is available on the National Bank of Belgium website:
https://www.nbb.be/fr/news-events/events/congres-des-economistes-les-finances-publiques-defis-daujourdhui-solutions-de

(Note: Philippe Aghion, co-author of the paper, is now a Nobel laureate.)

I3h New Publication - Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation

We are pleased to highlight the recent publication by Sanae Akodad, Xixian Niu, Berta Secades, and Hilde Stevens, entitled “Impact of Drug Repurposing between 1985 and 2024 on Pharmaceutical Innovation,” published in Communications Medicine. The article examines the role of drug repurposing as a strategic pathway for pharmaceutical innovation over the past four decades, drawing on a comprehensive analysis of regulatory approval data in the United States.

Read more in Communications Medicine

I3h Student Sanae Akodad - PhD Defense

We are very pleased to announce that Sanae Akodad has successfully completed her private PhD defense on January 6.

The title of her thesis is “Multidimensional Analysis of the Burden of Rare Diseases: The Case of Spinal Muscular Atrophy.”

Her doctoral research was conducted under the supervision of Prof. Hilde Stevens (I3h).

We warmly congratulate her on this important milestone.

Michel and Serge Goldman publish a new OpEd in Le Soir

Between collective anxiety and uncertainty, today’s youth—Generation Z—find themselves on high alert once again. In this OpEd, brothers Michel and Serge Goldman explore fears of a return of the epidemic after the traumatic experience of COVID-19, while examining psychological resilience, social engagement, and the ability to bounce back: personal and collective challenges that are redefining young people’s relationship with the future.

Read on Le Soir

Florence Horicks shares insights from hosting the Symposium for More Patient Value

By Symphony of Us

Last week the Symphony of Us participated in the second Citizen Science 4 Health conference in Zürich!

Two days that brought together 150 academics, care professionals and citizens scientists.

Inspiring to see how worldwide collaborative, transdisciplinary projects guided by the values of patients are rising!

Join the conversation on LinkedIn

Florence Horicks shares insights from hosting the Symposium for More Patient Value

By Symphony of Us

Yesterday, our team had the pleasure of hosting the Symposium for More Patient Value bringing together patients, healthcare professionals, researchers and artists.

Throughout the day, we explored how patient value can be created across the levels of the healthcare ecosystem:

  • Micro level: improving the patient experience in everyday care
  • Meso level: transforming practices and organizational models to better serve patient needs
  • Macro level: securing health data (re)use, shaping policies and system-wide strategies that enable meaningful impact

The contributions of patient were particularly powerful, reminding us that co-creation is essential if we want to design solutions that truly resonate with their needs.

Thank you to all participants, speakers, and partners for your insights and your commitment to advancing patient value. We are deeply grateful to our patient-researchers for their trust and their commitment.

This was the closing event of our wonderful project The Symphony of Us. Looking forward for the next steps to creating value for patients at every level of the system.

Join the conversation on LinkedIn

Symposium Patient Value in Oncology Research & Care
United for Change: Transdisciplinary Paths to Patient Value in Oncology

By Symphony of Us

Symphony of Us

Join the Symphony of Us Team for a unique gathering of minds committed to advancing patient value in oncology.

This one-day symposium will bring together researchers, healthcare professionals, patient representatives, policymakers, NGOs, and others working at the intersection of science, care, and societal impact.

As a closure event, it will be the occasion to share what we have learned during the Symphony of Us project and to bridge our findings and experiences with yours. Let’s further explore, discuss, and inspire new ways of putting patient value at the heart of oncology research and practice together!

November 25th 2025
USquare Brussels, Kroonlaan 227, 1050 Elsene
Register here: https://forms.office.com/e/Qqsfg7vv1k

Are you also driven by Patient Value in oncology, share what you do by submitting an abstract!

Abstract Submission is Open
Deadline: 01/09/2025
Submission: Symposium for more Patient Value – The Symphony of Us

Hope to see you there!

Registrations and submissions

Getting Ready for Trouble

How can we communicate better for evidence-informed policy-making in crisis management?

Join us in Brussels for a 2-day symposium & workshop bringing together policymakers, stakeholders, and leading researchers to explore communication challenges in pandemic preparedness and response.

Getting ready for trouble

Register here

Societal participation in the development of orphan drugs: a systematic review

The development of orphan drugs (ODs) remains constrained by structural barriers, including limited scientific knowledge, high clinical uncertainty, and fragile commercial incentives. In parallel, an alternative ecosystem has emerged in which non-commercial societal actors (patients, advocacy groups, and philanthropic entities) contribute to the design, evaluation, and dissemination of therapies for rare diseases. This systematic review provides the first structured synthesis of empirical evidence on societal participation in OD development, with a specific focus on neuromuscular and neurodegenerative disorders. Twenty-one peer-reviewed studies were included, spanning a range of designs from case reports to stakeholder surveys.

Read More

Michel Goldman: A Teacher Until the End

In a quiet Brussels morning, we sat down with Dr. Michel Goldman, 70, a world-renowned immunologist, the founding president of the Institute for Interdisciplinary Innovation in Healthcare (I3h), and former executive director of the €2 billion Innovative Medicines Initiative. But his story is not just one of science and leadership; it is also personal. Goldman is a lymphoma patient. A scientist who spent decades studying lymphocytes, cells that one day had turned against him.

https://cancerworld.net/michel-goldman-a-teacher-until-the-end/

Read More

TMex (Translational Medicine explained) 2025 course announcement

By EATRIS

Want to learn how your research is translated into patients benefit?
Join EATRIS in Barcelona for the Translational Medicine Explained Tmex 2025 course!

Dates: 11-14 November 2025
Place: Barcelona, Spain

Turn science into solutions
The translation of biomedical discoveries into products which provide patient benefit requires a truly multidisciplinary effort. Along the development path, academic / clinical researchers, lawyers, business developers, funders, regulators and patients need to work hand-in hand to allow for a fast and cost-effective process. Many researchers, however, do not have the opportunity to examine the process in more detail and may as a result be missing out on opportunities to take their work further, or work in a less efficient manner.

TMex is an interactive 4-day course, taught by experts who focus on different aspects of the translational path. The course aims to provide hands-on learning, where participants have the opportunity to apply key knowledge and skills to real-life scenarios as they learn them. Open to anyone with an interest in learning more about Translational research and applying it to their own work and research, the course is further enhanced by a series of short e-learning modules which are completed at your own pace prior to attending the face-to-face course.

At the end of the course, participants will be able to:
· Describe the key steps and questions to be addressed in translating scientific discoveries into medical products
· Define the multidisciplinary stakeholders involved in translation and the importance of strong partnerships in improving the pathway
· Recognise the importance of interacting with patients from their viewpoint and demonstrate strategies for engagement
· Examine key translational medicine bottlenecks and opportunities

Additionally, the course will provide participants with the chance to develop their individual professional skills. These will include opportunities to develop their teamwork and communication skills during interactive workshop sessions, through to building their network across all course members and learning more about career options open to them in Translational research.

“The TMex course has given me essential insights about my current research projects, the direction I need to take the research in and also about my future career. I would definitely recommend this course for anyone interested in Translational Medicine!” Rebecca Andersson, IDIBELL, Barcelona, Spain

More information and registration

Bridging science, business & innovation

The Advanced Master in Biotech & MedTech Ventures is where leadership meets life science innovation. Whether you come from a science, engineering, or business background, this programme equips you with venture creation skills, market strategy expertise, and deep industry insights to assume a C-suite position at an early-stage Biotech or MedTech company.

Work on real challenges, connect with industry leaders and take the next step in shaping the future of life sciences.

Applications are open – start your journey today! https://bit.ly/3XWBl33

Applications

Competition-friendly industrial policy

By Philippe Aghion, Mathias Dewatripont & Patrick Legros

Industrial policy, essential for addressing market failures, encounters concerns regarding protecting inefficient firms. We advocate for competition-friendly industrial policies, underscoring the complementary relationship between industrial and competition policies and the benefits of targeted sector-specific subsidies. We emphasize the significance of market competitiveness for sustainable industrial development, drawing from theoretical models and empirical evidence from China.

Read the article

Implementing an integrative oncology pathway in a comprehensive cancer center: expert insights and perspectives

Integrative oncology (IO) has evolved into an evidence-informed discipline endorsed by major oncology organizations. However, integrating IO into standard oncology care remains a challenge, often dependent on institutional culture and provider attitudes. This exploratory pilot study aimed to assess healthcare professionals’ (HCPs) knowledge, communication practices, perceived needs, and perspectives regarding IO in a Belgian Comprehensive Cancer Center with no preexisting IO pathway.

Read the article

Learning through play: Discovering drug development with Repurpolis Board Game

This morning, we had the pleasure of diving into the fascinating world of drug development through the engaging Repurpolis Board Game organized by Rosan Kreeftmeijer-Vegter. Far more than just entertainment, the game provided an insightful journey, illustrating the critical path a medication must follow before it becomes available to patients.

Drug Repurposing board game
More details

Donner voix aux patients en oncologie

Florence Horicks of I3h talks about patient advocacy in Esprit Libre

Drug Repurposing board game
More details

Register for I3h Interdisciplinary Program in Healthcare Innovation

I3h Institute's Interdisciplinary Program in Healthcare Innovation
    • November 16, 2026 - 12:30 to 14:00
    • Reading seminar by Nicolas van Zeebroeck

    • TBA

      Speaker: Nicolas van Zeebroeck, Professor of Digital Economics & Strategy.

      Online seminar: Online via Teams: Register here.